Form 4: Ligand Pharmaceuticals CLO Andrew Reardon Reports Stock Transactions

Andrew Reardon, CLO & Secretary of Ligand Pharmaceuticals, reports acquisition and disposal of common stock related to vesting of performance and restricted stock units.

Summary

• On February 14, 2025, Andrew Reardon acquired 6,928 shares of common stock upon vesting of performance stock units (PSUs) and 5,429 shares of common stock upon vesting of restricted stock units, both at $0.0.
• Also on February 14, 2025, 2,775 shares were disposed of at $120 to cover tax liabilities related to the PSU settlement, and 1,758 shares were disposed of at $120 to cover tax liabilities related to the restricted stock unit settlement.
• On February 15, 2025, 1,114 and 876 shares were disposed of at $120 to cover tax liabilities related to the settlement of restricted stock units.
• Following these transactions, Reardon directly owns 28,368 shares of Ligand Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for publicly traded companies, ensuring transparency in insider trading activities.
• The transactions reported are typical for executives receiving stock-based compensation and selling shares to cover tax obligations, a common practice across the pharmaceutical industry and other sectors.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly diluting the stock.

Key Dates

Keywords

Ligand Pharmaceuticals, LGND, Andrew Reardon, Form 4, Stock Transactions, Performance Stock Units, Restricted Stock Units, Beneficial Ownership